Next Phase Newsletter

A venture capital firm with several offices in Western Europe specializes in early-stage and growth capital investments in the Technology and Life Sciences sectors. The firm has approximately $1B AUM and is currently investing out of a dedicated Life Sciences fund. Depending on the stage of the company, the firm can allocate up to $15M over the life of the investment. The firm can also lead or co-lead financing rounds of up to $30M or higher with syndication. The firm focuses on European companies but will consider US-based companies with activities in Europe. The firm is actively seeking new investment opportunities.

In the life sciences sector, the firm in therapeutics, medical technology, diagnostics, and digital medicine, and is opportunistic in terms of subsectors and indications. In therapeutics, the firm mainly focuses on early-stage companies with preclinical proof of concept data or about to enter the clinic, with a preference for companies developing highly innovative technology platforms. In diagnostics and medtech, the firm prefers companies with product candidates (with strong IP protection) approaching regulatory approval or companies who have already launched a first product. In digital medicine, the firm looks for data-driven technologies being applied clinically to drive meaningful change in patient outcomes.

The firm typically requests a board seat and looks for a strong and experienced management team, but will also support highly talented fledgling entrepreneurs.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A pharmaceutical arm of a Japan conglomerate with multiple business operations, including a USA-based licensing and clinical development office and a Japan-based sales division, is seeking to form partnerships and in-licensing relationships regarding early stage assets in its key indication areas. These partnerships are highly flexible, and may involve the firm contributing personnel, sharing studies and research tools, or providing research expense funding.

The firm is interested in early-stage, first-in-class, orally active small molecule NCEs. The firm seeks assets in the following key areas: metabolic disease (type 2 diabetes and its complications, dyslipidemia, NASH, and energy metabolism in Alzheimer’s disease), infectious disease (functional cures for HIV and Hepatitis B), cardiovascular disease (CHF, peripheral arterial disease and pulmonary arterial hypertension), autoimmune disease (multiple sclerosis, lupus, IBD, systemic scleroderma, and organ fibrosis). Additionally, the firm is interested in sarcopenia & cachexia, chronic kidney disease, pain (peripheral targets), and osteoporosis (osteogenesis only). As well as drugs, the firm is interested in drug targets in these disease areas. The firm is open to forming partnerships regarding very early stage assets, at or prior to the lead optimization phase.

For in-licensing for the Japan market, the firm is focused on renal diseases, dermatology and allergic diseases.

The firm also invests in drug discovery technologies and research tools such as: technologies related to translational research using cell culture, isolated cellular organelles and related mechanisms; HTS technologies; protein structure analysis; chemical biology, chemical synthesis, and chemical libraries; biophysical tools; in silico technologies; biomarkers and bioinformatics screening, biomarker research, and compound libraries.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with multiple offices throughout Europe recently raised a new fund of EUR 80 million in 2019, and invests alongside a network of over 200 private investors across several industries including the Life Sciences. The firm and its investors typically co-invest with other institutional investors for Life Science investments. The firm prefers to invest in later rounds where no further dilution will occur before an exit. The firm and its network typically allocate €1-5M (in equity/convertible loan) over the life of an investment. Normally each investor in the firm’s network invests between €50K and €2M. The firm primarily invests in companies that are based in the D-A-CH region where the firm has a strong footprint, but will consider compelling opportunities globally. The firm is actively seeking new investment opportunities.

The firm makes highly selective investments in medical devices, diagnostics and in enabling technologies in the biotech sector, including genomic and proteomic sequencing. The firm is currently more interested in diabetes, CNS, and oncology but is generally open to all indications. For medical devices, the firm looks for devices that have some proof-of-concept and is agnostic in terms of technology types.

The firm prefers to co-invest with other institutional Life Science investors, particularly for opportunities outside the D-A-CH region; it is preferred that companies based elsewhere have a lead investor in place before approaching the firm.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A leading independent venture capital firm in Western Europe provides private equity financing to early- and mid-stage human healthcare and life science companies. The firm has raised two funds, and generally allocates $4-7M (in equity) per company, always co-investing with other specialized investors and during the whole life of the investment. The firm is currently prioritizing opportunities in Europe.

The firm invests in innovative therapeutics. The firm focuses on indications with a clear unmet need, and prefers to invest in opportunities that have realistic exit potential in 2-3 years. In case of niche/orphan indications, the potential market share should be significant and realistic. The firm invests in small molecules, biologics and advanced therapies. At minimum, the product should have solid animal data.

The firm looks for a cohesive management team with a proven track record, including relevant business experience and top-notch scientific know-how. The firm requires a board seat in each portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture firm founded in 2008 with multiple offices in China has a total fund size of $5 Billion USD. The firm is interested in companies raising seed/angel to Series A rounds and provides investments that can range up to $50M depending on the opportunity. Series B round will also be considered occasionally in terms of the potentiality. The firm seeks opportunities globally, though it has a preference for companies based in China.

The firm is interested in therapeutics, medical devices without drug components, in-vitro diagnostics, and healthcare IT. The firm is interested in preclinical to early-stage clinical (Ph I-II) technologies. The firm is indication agnostic, though highly prefers technology with a China market angle.

The firm does not have a management team requirement and will help support early-stage companies with filling management teams, if necessary.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A corporate venture capital arm of a leading global insurance company headquartered in Western Europe will generally allocate $1-5M for up to 20% equity stake, and selectively does convertible financing as well. The firm does not invest strictly for financial returns and seeks a strategic relationship with the companies they invest in. The firm  will typically participate in Series A and B rounds. The firm anticipates 4-5 investments per year, although this number is subject to fluctuate depending on deal flow. The firm will invest in technologies that will impact regions where the firm has a footprint.

In the life sciences space, the firm seeks innovative technologies that can disrupt and transform the future of insurance. The firm will not consider therapeutics or biopharma opportunities. Any technology with implications to the insurance industry will be considered, including smart diagnostics, genomics, etc. Previously, the firm has expressed interest in technology that helps with chronic disease management and considered telemedicine companies as well. In terms of diagnostics, the firm expects the technology to be undergoing promising clinical trials that contribute to its validation. For companies that fall into the digital health sector, the firm expects some ongoing traction and key partnerships to be in place.

The firm seeks to work with companies backed by a full management team with strong industry expertise. Ideally, the team will have a strong life sciences background and an experienced advisory team, with good understanding of how their product or technology works. The firm can act as the lead or co-investor and will most likely take a board seat if they were to lead.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm founded in 2016 is focused on cross-border investments. When investing, the firm doesn’t only provide financial capital, they also provide their global consulting services focused specifically on helping companies work across borders and in China. Currently, the firm is partnered with the Chinese Government to bring good projects from North America to China and are focused on technologies that are at an advanced stage with patents that are willing to launch in Chinese markets or to set up factories and labs in China. The firm is however, willing to invest smaller amounts in good opportunities that have no interest/fit for the Chinese markets as well. The firm’s major focus within the life sciences is biotech and is focused on seed to series B rounds. The firm generally invests up to $10M USD for Series A deals, is flexible for series B rounds, and invests up to $1M USD for seed stage rounds.

Within the Life Sciences space, the firm is specifically focused on clinical tests, therapeutics, and other biotech technologies. The firm is also interested in medical devices focusing on large disease areas within China such as diabetes and cancer. Additionally, the firm is focused on technologies within these sectors that have a good fit with the Chinese Market or have a strong interest in working in China.

When investing, the firm looks to take a board seat. The firm provides consulting, localization services, and the ability to leverage resources in China to help the company grow alongside their direct equity investment and believe that these abilities can be best leveraged with a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.